Drug intelligence / Profile preview

177Lu-NARI-FAPI-1.21

Development stage
Preclinical
Lead developer
National Atomic Research Institute
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

177Lu-NARI-FAPI-1.21 is a radiolabeled, long-acting fibroblast activation protein (FAP) inhibitor (FAPI) developed by the National Atomic Research Institute (NARI) in Taiwan [EP-0094]. The drug consists of the FAPI precursor NARI-FAPI-1.21 (supplied by Kelowna International Scientific) radiolabeled with Lutetium-177 (177Lu) [EP-0094]. It is designed to target FAP, which is highly overexpressed on cancer-associated fibroblasts (CAFs) in the tumor microenvironment of various solid tumors [EP-0094]. Preclinical studies in HEK-293-FAP solid tumor models have demonstrated that 177Lu-NARI-FAPI-1.21 has favorable cell-binding properties, prolonged in vivo circulation, and enhanced long-term accumulation at tumor sites, making it a promising candidate for targeted radionuclide therapy and SPECT/CT imaging [EP-0094].

Other names
177Lu-labeled NARI-FAPI-1.21Lu-177-NARI-FAPI-1.21Lu177-NARI-FAPI-1.21Lu 177-NARI-FAPI-1.21
02

Identity

Drug type
Radiopharmaceuticals
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesBeta-minus EmittersGamma Emitters
03

Pharmacology

Route
Intravenous
04

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

05

Companies

  • National Atomic Research InstituteLead developer
06

Competitive landscape

Drugs on the same target
95

Most advanced

  1. gemigliptinPhase 4
  2. 68Ga-FAPIPhase 4
  3. GEH300079 (68Ga)Phase 3
  4. talabostatPhase 3
  5. [18F]-FAPI-74Phase 3

Beyond the preview

Go deeper on 177Lu-NARI-FAPI-1.21.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-NARI-FAPI-1.21.

Work on 177Lu-NARI-FAPI-1.21? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call